Drug Approval | May 18, 2025
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
The product will be launched in Q1FY26
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals
No safety signals related to the vaccine candidate were identified
The biosimilar Ustekinumab has been developed and manufactured by the company
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
